GSK Bio
NEWS
Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to hone her leadership team with a hire who will focus on potential research and development deals.
Mylan Rumored to be in Discussions to Buy Merck KGaA’s Consumer Health Business, but Mylan Denies It
Mylan is reportedly in top-level talks with Germany’s Merck KGaA to buy its consumer health business. However, Mylan has denied it.
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to trim excess fat from the company. This morning the company announced it has divested its rare disease gene therapy portfolio to Orchard Therapeutics.
Pfizer Inc. may have a new potential buyer for its consumer health business unit. Mega-consumer goods company Procter & Gamble is reportedly interested in acquiring the business.
Dermavant Sciences, a company founded by biotech guru Vivek Ramaswamy, tapped former GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer.
Following an agreement to sell its share of a consumer health business unit to GlaxoSmithKline for $13 billion new Novartis Chief Executive Officer Vasant Narasimhan has some excess cash to use to shape the company in the coming years.
As Novartis locks in on a $13 billion deal with GlaxoSmithKline (GSK), Novartis chief executive officer Vasant Narasimhan confirms that any decision about spinning off its Alcon eye care business won’t be made until the first half of 2019.
GlaxoSmithKline walked away from a potential deal to acquire Pfizer’s consumer health unit four days ago and instead opted to acquire the stake controlled by Novartis. The deal will give GSK 100 percent ownership of the business unit.
JOBS
IN THE PRESS